Earn points on every order · Free shipping on orders over $159 · New products in stock
← Back to Compound Library
Fat Loss and Metabolism

MAZDUTIDE

Another GLP-1 + glucagon dual agonist, like survodutide, but generally smoother on the stomach. Curbs appetite and nudges up energy expenditure.

Research referenceCommunity compiled
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

Another GLP-1 + glucagon dual agonist, like survodutide, but generally smoother on the stomach.

Curbs appetite and nudges up energy expenditure.

What It Does

Mazdutide is a GLP-1 / glucagon receptor dual agonist (an OXM-based analog).

GLP-1 drives satiety and slowed gastric emptying; glucagon adds energy expenditure and hepatic fat effects.

Reported to be less nausea-inducing than survodutide.

Once-weekly with a simple 4-step titration.

Reconstitution

Vial SizeBAC Water / SolventConcentration
10 mg+ 2 mL5 mg/mL
Interactive tool

Reconstitution Calculator

Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.

Calculated concentration—Enter both values above.
Optional conversion

Enter a target amount you already have and select the syringe capacity.

Calculated draw—Enter concentration inputs and a target amount.

Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.

Protocol

PhaseFrequencyAmountNotes
Weeks 1–4Once weekly1.5 mgStart here; smoother GI profile than survodutide.
Weeks 5–8Once weekly3 mg
Weeks 9–12Once weekly4.5 mg
Week 13+Once weekly6 mgMaintenance. Many cap at 4–6 mg, especially if stacked.
Cycle & Timing

4-step titration over ~12–16 weeks to 6 mg/week maintenance; each step lasts 4 weeks.

Timing

same day each week, any time. Note: still raises heart rate via glucagon agonism, monitor.

Population Considerations

Women lose more than men at the same dose but report more GI (start lower). In PCOS they improve cycles, lower free testosterone and raise ovulation; a real unplanned-pregnancy risk. Stop before conceiving. Men: In men, excess fat lowers testosterone; GLP-1 raises total testosterone, SHBG and gonadotropins as weight drops, and improves sperm and erectile function; and preserves fertility, unlike TRT (which suppresses spe Women lose more than men at the same dose but report more GI (start lower). In PCOS they improve cycles, lower free testosterone and raise ovulation; a real unplanned-pregnancy risk. Stop before conceiving. Men: In men, excess fat lowers testosterone; GLP-1 raises total testosterone, SHBG and gonadotropins as weight drops, and improves sperm and erectile function; and preserves fertility, unlike TRT (which suppresses sperm).

Handling & Stacking

Injection site
SubQ, abdomen/thigh. Rotate.
Storage
  • Freeze-dried: -4°F.
  • Reconstituted: 36–46°F.
  • Best used within ~3–4 weeks, kept cold (structure-based estimate, no published data); that is close to the 28- day sterility limit, so use whichever comes first.
Side effects
Nausea, diarrhea, decreased appetite, mild heart-rate increase. Generally better tolerated than survodutide.
What to expect
  • Appetite suppression plus a metabolic-rate effect; steady weight loss over months.
  • Investigational outside its approval region.
  • Supply math 10mg → 6 vials (16-wk titration to 6 mg/wk)
Pairs well with
Lipo-C / L-Carnitine (metabolic support). Standalone incretin, do not combine with other GLP-1s
Avoid
Personal/family history of medullary thyroid carcinoma or MEN2. Prior pancreatitis. Pregnancy. Other incretin stacks

Safety & Patient Education

Contraindications
Personal/family history of medullary thyroid carcinoma or MEN2 (GLP-1 class warning) Prior pancreatitis Pregnancy and lactation Severe gastroparesis
Warnings
Thyroid C-cell tumor signal in rodents (GLP-1 class) Gallbladder disease with rapid weight loss Heart-rate increase from glucagon agonism Investigational outside its region of approval
Drug interactions
Insulin / sulfonylureas: hypoglycemia risk, adjust and monitor Delayed gastric emptying alters oral drug absorption Other GLP-1 agents: do not combine
Labs
  • Fasting glucose / HbA1c (baseline + periodic) Liver enzymes; lipase if pancreatitis suspected Resting heart rate / blood pressure Renal function with significant GI losses Out of range?
  • Rising glucose/HbA1c = blood sugar creeping toward diabetes (recheck, tighten diet); a falling eGFR = kidney strain, usually dehydration (hydrate, hold the dose).
Stop criteria
Severe persistent abdominal pain (pancreatitis) Persistent vomiting / dehydration Sustained tachycardia Pregnancy
Patient education
Smoother than survodutide but still titrate stepwise Hydrate and keep protein intake up Don’t combine with other GLP-1 / incretin drugs Stop and seek care for severe abdominal pain or persistent vomiting
References
researchdosing · peptidedosages · PubMed · clinicaltrials.gov · GLP-1 sex differences · Jensterle 2020